Fayuvi Adds a New Revenue Stream, but Ultragenyx’s 2027 Goal Faces Pressure
The FDA approval opens a route to sales, while a failed Angelman trial and ongoing losses complicate Ultragenyx’s path to profitability.
Makkler Newsroom · Sep 24, 12:38 AM · 1 min read